Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | The critical role of SIRT3 in lymphomagenesis

Ari Melnick • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

Ari Melnick, MD, Weill Cornell Medical College, New York, NY, discusses his group’s most recent research into lympomagenesis. Prof. Melnick discusses the role of non-oncogene addiction to SIRT3. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Ari Melnick

Precision epigenetic therapy for B-cell lymphoma 7:18
Precision epigenetic therapy for B-cell lymphoma
Ari Melnick • 20 Jun 2019
Epigenetic alleles: an emerging concept 2:45
Epigenetic alleles: an emerging concept
Ari Melnick • 25 Feb 2019
Translating epigenetic therapy to the clinic: rational combinations 5:24
Translating epigenetic therapy to the clinic: rational combinations
Ari Melnick • 24 Feb 2019
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management? 8:13
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Ari Melnick et al. • 2 Mar 2018

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals